Results 51 to 60 of about 781,343 (307)

Assembly 12: interstitial lung diseases [PDF]

Breathe, 2018
Meet @ERStalk Assembly 12: interstitial lung diseases http://ow.ly/Bp0730m9zX4.
Antoniou, Katerina, Trachalaki, Athina, Bibaki, Eleni, Poletti, Venerino   +3 more
openaire   +3 more sources

Overnight desaturation in interstitial lung diseases: links to pulmonary vasculopathy and mortality

ERJ Open Research
Background Overnight desaturation predicts poor prognosis across interstitial lung diseases (ILDs). The aim of the present study was to investigate whether nocturnal desaturation is associated with pulmonary vasculopathy and mortality.
George A. Margaritopoulos, Athanasia Proklou, Athina Trachalaki, Diana Badenes Bonet, Maria Kokosi, Vasilis Kouranos, Felix Chua, Peter George, Elisabetta A. Renzoni, Anand Devaraj, Sujal Desai, Andrew G. Nicholson, Katerina M. Antoniou, Athol U. Wells   +13 more
doaj   +1 more source

Patient perspectives on home-spirometry in interstitial lung disease: a qualitative co-designed study

BMJ Open Respiratory Research, 2023
Background Opportunities for home-monitoring are increasing exponentially. Home- spirometry is reproducible and reliable in interstitial lung disease (ILD), yet patients’ experiences are not reported.
Sarah Lines, Michael Gibbons, Rebecca Shuttleworth, Anne-Marie Russell, Graham Brown, Anna Duckworth, Alex Berry, Jessica Mandizha, Joseph W Lanario, Ana Paiva, Victoria Elworthy, Veena Muraleedharan, Ana Jorge Da Ponte, Howard Almond, Carole Bond, Maureen Cosby, Joanne Dallas, Marium Naqvi, Adam David Russell, Christopher J Scotton   +19 more
doaj   +1 more source

Prognostic value of serum oncomarkers for patients hospitalized with acute exacerbation of interstitial lung disease

Therapeutic Advances in Respiratory Disease
Background: Different types of inflammatory processes and fibrosis have been implicated in the pathogenesis of interstitial lung disease (ILD), a heterogeneous, diffuse, parenchymal lung disease.
Cuirong Ba, Chunguo Jiang, Huijuan Wang, Xuhua Shi, Jiawei Jin, Qiuhong Fang   +5 more
semanticscholar   +1 more source

Predictors of progression in systemic sclerosis patients with interstitial lung disease

European Respiratory Journal, 2020
Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc.
O. Distler, S. Assassi, V. Cottin, M. Cutolo, S. Danoff, C. Denton, J. Distler, A. Hoffmann-Vold, S. Johnson, U. Müller Ladner, V. Smith, E. Volkmann, T. Maher   +12 more
semanticscholar   +1 more source

Increased expression of 5-hydroxytryptamine(2A/B) receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention [PDF]

, 2010
Background Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited responsiveness to available treatments. It is characterised by epithelial cell injury, fibroblast activation and proliferation and extracellular matrix deposition ...
Amarie, Oana Veronica, Dumitrascu, Rio, Eickelberg, Oliver, Grimminger, Friedrich, Königshoff, Melanie, Reiter, Rudolf, Schermuly, Ralph Theo, Seeger, Werner, Udalov, Sergey   +8 more
core   +1 more source

Methotrexate and rheumatoid arthritis associated interstitial lung disease

European Respiratory Journal, 2020
Question addressed by the study Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA.
P. Juge, Joyce S. Lee, J. Lau, Letícia Kawano-Dourado, J. Serrano, M. Sebastiani, G. Koduri, E. Matteson, K. Bonfiglioli, M. Sawamura, R. Kairalla, L. Cavagna, E. B. Cassione, A. Manfredi, M. Mejía, P. Rodríguez-Henríquez, M. González-Pérez, R. Falfán-Valencia, I. Buendía-Roldán, G. Pérez-Rubio, E. Ebstein, Steven Gazal, Steven Gazal, R. Borie, S. Ottaviani, C. Kannengiesser, B. Wallaert, Y. Uzunhan, H. Nunes, D. Valeyre, N. Saidenberg-Kermanac’h, M. Boissier, L. Wémeau-Stervinou, R. Flipo, S. Marchand-Adam, Pascal Richette, Pascal Richette, Y. Allanore, Y. Allanore, C. Dromer, M. Truchetet, C. Richez, T. Schaeverbeke, H. Lioté, G. Thabut, K. Deane, J. Solomon, T. Doyle, J. Ryu, I. Rosas, V. Holers, C. Boileau, M. Debray, R. Porcher, D. Schwartz, R. Vassallo, B. Crestani, P. Dieudé   +57 more
semanticscholar   +1 more source

Familial Interstitial Lung Disease

Seminars in Respiratory and Critical Care Medicine, 2020
AbstractThe interstitial lung diseases (ILDs) are a group of progressive disorders characterized by chronic inflammation and/or fibrosis in the lung. While some ILDs can be linked to specific environmental causes (i.e., asbestosis, silicosis), in many individuals, no culprit exposure can be identified; these patients are deemed to have “idiopathic ...
openaire   +3 more sources

Recent advances in the treatment of systemic sclerosis associated interstitial lung disease

Frontiers in Medicine, 2023
Connective tissue diseases (CTDs) are a heterogenous group of systemic inflammatory disorders. The development of connective tissue disease-associated interstitial lung disease (CTD-ILD) is a key complication associated with significant morbidity and ...
Antoniya Kamenova, Argyris Tzouvelekis, George A. Margaritopoulos   +2 more
doaj   +1 more source

Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players

International Journal of Molecular Sciences, 2021
Interstitial lung diseases (ILDs) that are known as diffuse parenchymal lung diseases (DPLDs) lead to the damage of alveolar epithelium and lung parenchyma, culminating in inflammation and widespread fibrosis.
A. V. Samarelli, R. Tonelli, A. Marchioni, G. Bruzzi, F. Gozzi, D. Andrisani, I. Castaniere, L. Manicardi, A. Moretti, L. Tabbì, S. Cerri, B. Beghé, M. Dominici, E. Clini   +13 more
semanticscholar   +1 more source